Warning Letter — Extra Medication / www.extramedication.com
The FDA issued a warning letter to Extra Medication (www.extramedication.com) for the sale and distribution of unapproved and misbranded drug products through their website.
This affects the operators of the website Extra Medication, as well as regulatory and compliance departments involved in the oversight of online drug distribution and pharmaceutical e-commerce.
The issuance of this letter by CDER underscores continued federal scrutiny of online entities bypassing the drug approval process. It suggests a low tolerance for digital platforms that distribute medications without requiring valid prescriptions or adhering to safety labeling standards, posing significant legal and regulatory risks for unauthorized distributors.
Companies operating online pharmacies must ensure all distributed drug products have valid FDA approvals and that dispensing practices strictly adhere to prescription requirements. Compliance and legal teams should audit digital storefronts to ensure no unapproved molecules or misbranded products are being marketed to U.S. consumers.
FDA Warning Letter issued to: Extra Medication / www.extramedication.com. 06/23/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/extra-medication-wwwextramedicationcom-725152-06232026
Open in openFDA / FDA.gov